Talk:Multi-dose vial

Merge proposal. Cross-posting the narrower version of the proposal from Talk:Vial, where the full merge was withdrawn: the coring and self-sealing material is currently duplicated in both articles and the two versions disagree about whether needle gauge or repeated penetration dominates. Propose the mechanism lives at Vial and this article keeps a short summary with a pointer. — — StopperingSteff (talk) 09:33, 25 March 2025 (UTC)

Support. The mechanism is a property of the closure, so it belongs in the closure article. What this article needs is the consequence specific to repeated entry — that the probability accumulates over twenty punctures — which is not a mechanism claim and can stand alone. — — SyringeSybille (talk) 12:41, 25 March 2025 (UTC)

Support, with one condition: the accumulation point must survive the trim. It is the only genuinely multiple-dose-specific thing in the passage and it is currently the sentence most likely to be cut as redundant. — — EndotoxinEd (talk) 10:05, 26 March 2025 (UTC)

Done as described. The disagreement about the dominant factor is resolved in favour of what <381> actually supports, which is that the test characterises the closure and not the pattern of use — neither of our two versions was quite right. — — StopperingSteff (talk) 08:57, 2 April 2025 (UTC)

Request for comment. How should the article characterise a lyophilised peptide reconstituted with bacteriostatic water? Options canvassed on this page have been: (a) a preserved multiple-dose preparation; (b) a preparation containing a preservative but with no demonstration of effectiveness; (c) a single-dose preparation, since the compendial demonstration attaches to finished formulations only.

This has been argued three times in eight months and the article has carried all three characterisations at different points. — — RfC_Rasmus (talk) 10:00, 20 January 2026 (UTC)

(b). It is factually a preparation containing 0.9% benzyl alcohol; that is not in dispute. What is absent is the <51> demonstration, which is made on a specific finished formulation and cannot be inherited from a diluent. Option (a) asserts something untested and option (c) denies something true. — — EndotoxinEd (talk) 12:34, 20 January 2026 (UTC)

(b), and the reason to be precise is that the missing element is checkable in principle. Anyone could run the test on a representative reconstituted preparation. Saying so tells the reader where the uncertainty is rather than resolving it by fiat in either direction. — — BacWaterBarnaby (talk) 09:12, 21 January 2026 (UTC)

(b) with a note that compounding practice would treat it as (c). From a regulatory standpoint a preparation without a demonstrated preservative system does not get multiple-dose dating, so the practical answer under <797> is the conservative one. Both facts are true and the article can say both. — — Compounding_Cate (talk) 11:48, 22 January 2026 (UTC)

(b). Agreeing, and flagging that whichever wording is chosen will be read as advice by some readers. The wording that is least likely to mislead is the one that names what is missing, because it neither reassures nor alarms. — — HarmReductionHen (talk) 08:30, 24 January 2026 (UTC)

Closing with consensus for (b), with Cate's addition that compounding practice under <797> would treat such a preparation conservatively. No participant supported (a). The section has been rewritten accordingly. — — Ref_Desk_Ron (talk) 10:15, 11 February 2026 (UTC)

§Documented infection events is one of the longest sections and its most memorable content — the Nevada outbreak — is an event in which the vial was arguably incidental. A reader will come away associating multiple-dose vials with hepatitis C transmission, when the transmissible act was syringe reuse. — — BalanceBirdie (talk) 13:07, 30 March 2026 (UTC)

The section says exactly that, twice, and the two-class framing at the top exists to prevent the inference you describe. I would resist shortening it: the reason the framing is necessary is that the association is widespread, and correcting a widespread association takes more words than asserting a fact. — — EndotoxinEd (talk) 16:22, 30 March 2026 (UTC)

I lean toward Ed. My only suggestion is that the section heading could carry the framing — something naming both the reservoir and the vector cases — so that a reader skimming the table of contents gets the distinction before the narrative. — — NPOV_Nadia (talk) 09:44, 31 March 2026 (UTC)

A heading change would satisfy most of my concern. I withdraw the length objection. — — BalanceBirdie (talk) 10:58, 1 April 2026 (UTC)

Thimerosal and chlorobutanol are in the table with concentrations. Both are largely out of use in injectables — thimerosal essentially withdrawn, chlorobutanol rare. Listing them alongside current preservatives without dates implies they are options a reader might encounter. — — LabelLibby (talk) 11:26, 8 June 2026 (UTC)

The thimerosal row says "largely withdrawn" in the notes column. Chlorobutanol does not, and should. I would keep both rows: readers do encounter older products and older literature, and a table that silently omits them is less useful than one that includes them with a status. — — EndotoxinEd (talk) 14:03, 8 June 2026 (UTC)

Agree with keeping. The chlorobutanol note about volatile loss on storage is itself the interesting fact — it is the clearest example of a preservative whose concentration is not constant, which the article discusses separately. — — PharmDrafts (talk) 09:17, 9 June 2026 (UTC)

Status added to the chlorobutanol row and the volatility point cross-referenced to the subsection. Satisfied. ✓ Done — — LabelLibby (talk) 08:52, 10 June 2026 (UTC)